Loading…
Skye Bioscience, Inc. is projected to rise to $0.6057 by 2027, a +4% move from its current price of $0.5842. SKYE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.5669 | $0.5839 | $0.6013 | -0.06% |
| Aug 6 | $0.5597 | $0.5835 | $0.6084 | -0.11% |
| Aug 7 | $0.5542 | $0.5832 | $0.6138 | -0.17% |
| Aug 8 | $0.5495 | $0.5829 | $0.6183 | -0.23% |
| Aug 9 | $0.5454 | $0.5826 | $0.6222 | -0.28% |
| Aug 10 | $0.5417 | $0.5822 | $0.6258 | -0.34% |
| Aug 11 | $0.5382 | $0.5819 | $0.6291 | -0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5382 | $0.5819 | $0.6291 | -0.39% |
| Week 2 | $0.5191 | $0.5796 | $0.6472 | -0.79% |
| Week 3 | $0.5044 | $0.5773 | $0.6608 | -1.18% |
| Week 4 | $0.492 | $0.575 | $0.6721 | -1.57% |
| Week 5 | $0.4811 | $0.5728 | $0.6818 | -1.96% |
| Week 6 | $0.4713 | $0.5705 | $0.6906 | -2.35% |
| Week 7 | $0.4623 | $0.5682 | $0.6984 | -2.73% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Skye Bioscience, Inc. is a clinical-stage biotechnology company that focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate nimacimab is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation.
The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
It is categorized in Healthcare.
Skye Bioscience, Inc. (SKYE) is currently trading at $0.5803, with a market cap of $20.39M, and a rank of 4589. The near-term forecast for 2026 shows min $0.577, avg $0.5803, max $0.6562, with sentiment Neutral.
Looking further, 2027 avg $0.6047 and 2028 avg $0.6464, followed by 2029 avg $0.7328 and 2030 avg $0.8607, indicating a gradual upward trajectory. In the long run, the forecasts project a significant rise by 2050, with avg $2.68, max $5.14 and ROI 361, and a bullish sentiment across the later years.
A major floor 18.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.6% away) — a key level to hold.
The nearest ceiling, 21.4% above — a clean break opens room to run.
A major ceiling 81.4% above — clearing it would confirm fresh momentum.
Key SKYE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SKYE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6004 | Sell | $0.5974 | Sell |
| MA 10 | $0.6263 | Sell | $0.6167 | Sell |
| MA 20 | $0.6465 | Sell | $0.6412 | Sell |
| MA 50 | $0.7048 | Sell | $0.6923 | Sell |
| MA 100 | $0.736 | Sell | $0.7901 | Sell |
| MA 200 | $0.9124 | Sell | $1.16 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.71 | Neutral |
| Stoch RSI (14) | 1.97 | Buy |
| CCI (20) | -157.66 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -6.11 | Sell |
| Bollinger %B (20,2) | 0.01 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.56 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 28.33 | Buy |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.58 | Buy |
| ADX (14) | 19.66 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is BEARISH, with RSI14 at 30. The nearby price action shows SMA50 at $0.7079 and SMA200 at $0.9171. The stock sits on support at $0.58 and faces resistance at $0.712. The 30-day price range runs from $0.4755 to $0.7081, and annualized volatility is 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.569 | $0.5842 | $0.66 | 0% | Neutral | |
| $0.4797 | $0.6057 | $0.8106 | +4% | Neutral | |
| $0.5008 | $0.6521 | $0.9085 | +12% | Neutral | |
| $0.5509 | $0.7359 | $1.06 | +26% | Bullish | |
| $0.628 | $0.8579 | $1.27 | +47% | Bullish | |
| $0.6149 | $0.8574 | $1.29 | +47% | Bullish | |
| $0.6096 | $0.8664 | $1.33 | +48% | Bullish | |
| $0.6058 | $0.8765 | $1.38 | +50% | Bullish | |
| $0.5885 | $0.8661 | $1.38 | +48% | Bullish | |
| $0.70 | $1.05 | $1.70 | +79% | Bullish | |
| $0.8393 | $1.35 | $2.34 | +132% | Bullish | |
| $1.46 | $2.67 | $5.08 | +357% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.569 | $0.5842 | $0.67 | +0.00% |
| September 2026 | $0.462 | $0.5475 | $0.6678 | -6.29% |
| October 2026 | $0.4647 | $0.5548 | $0.6847 | +1.35% |
| November 2026 | $0.4503 | $0.5408 | $0.6737 | -2.52% |
| December 2026 | $0.435 | $0.5254 | $0.66 | -2.85% |
Click any year to see its month-by-month SKYE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, SKYE could reach as high as $0.66, with a base case around $0.5842 and support toward $0.569 — roughly 0% from $0.5842. A consolidation phase looks the most probable path here.
Expect SKYE to range from $0.4797 to $0.8106 through 2027. The $0.6057 average target implies a +4% move from current prices. That is up +4% on the projected 2026 average. Price action looks broadly range-bound.
The SKYE price prediction for 2028 points to an average of $0.6521 (low $0.5008, high $0.9085) — a potential gain of +12% on today's $0.5842. A consolidation phase looks the most probable path here.
In 2029, SKYE is projected to trade between $0.5509 and $1.06, averaging $0.7359 — a potential gain of +26% from today's $0.5842. That is up +13% on the projected 2028 average. Momentum favours further upside here.
Skye Bioscience, Inc.'s 2030 outlook centres on $0.8579, within a $0.628 to $1.27 range. That is up +17% on the projected 2029 average. That marks a +47% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, SKYE could reach as high as $1.29, with a base case around $0.8574 and support toward $0.6149 — roughly +47% from $0.5842. Momentum favours further upside here.
Expect SKYE to range from $0.6096 to $1.33 through 2032. The $0.8664 average target implies a +48% move from current prices. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The SKYE price prediction for 2033 points to an average of $0.8765 (low $0.6058, high $1.38) — a potential gain of +50% on today's $0.5842. Momentum favours further upside here.
In 2034, SKYE is projected to trade between $0.5885 and $1.38, averaging $0.8661 — a potential gain of +48% from today's $0.5842. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
Skye Bioscience, Inc.'s 2035 outlook centres on $1.05, within a $0.70 to $1.70 range. That is up +21% on the projected 2034 average. That marks a +79% change versus current levels. Momentum favours further upside here.
By 2040, SKYE could reach as high as $2.34, with a base case around $1.35 and support toward $0.8393 — roughly +132% from $0.5842. Buyers look set to stay in control over this stretch.
Expect SKYE to range from $1.46 to $5.08 through 2050. The $2.67 average target implies a +357% move from current prices. That is up +97% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SKYE today (≈ 1,711.742554 SKYE) could be worth
$4,567.29
+$3,567.29 (+357%) by 2050 · US Dollar
Based on the average projected SKYE price of $2.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SKYEwould be worth at today's price.
$1,000 invested in SKYE on Jul 31, 2025 (≈ 280.11205 SKYE) would be worth
$163.64
-$836.36 (-83.6%) today · 0.16× · US Dollar
Based on a SKYE entry price of $3.57 vs. today's $0.5842.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.652 | $896.01 | -10.4% |
| 1 month ago | $0.675 | $865.48 | -13.5% |
| 3 months ago | $0.824 | $708.98 | -29.1% |
| 6 months ago | $0.93 | $628.17 | -37.2% |
| 1 year ago | $3.57 | $163.64 | -83.6% |
| All time (5.0y) ago | $38 | $15.37 | -98.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SKYE forecast.
Our base-case forecast reaches $1.20 around 2040.
Implied market cap at $1.20: $42.17M
The multi-year forecast turns bullish in 2029, with 2029 avg $0.7328 and ROI 26.3; 2030 avg $0.8607 and ROI 48.3. By 2035, avg $1.05 and ROI 80.6, and by 2040, avg $1.34 and ROI 130.5. The journey culminates in 2050 with avg $2.68 and ROI 361, with a max forecast of $5.14 and bullish sentiment continuing through the period.
These forecasts imply meaningful long-term upside from the 2029 onward, but they are estimates and carry inherent uncertainty and risk.
Tap a question to reveal the answer.
Avg $0.8607; Min $0.6269; Max $1.28; ROI 48.3; Sentiment BULLISH.
Forecasts show a neutral to bullish path in the near term, with 2026 avg $0.5803 and 2029 avg $0.7328, rising to 2030 avg $0.8607 and ROI 48.3. From 2029 onward the sentiment is BULLISH and the long-term outlook projects strong upside to 2050 (avg $2.68, ROI 361, max $5.14). These are estimates, not guarantees.
Yes, the max forecast in 2050 is $5.14.
Current price: $0.5803; Market cap: $20.39M.
The 30-day range is $0.4755 to $0.7081.
Skye Bioscience, Inc. Community Discussion
0Share your Skye Bioscience, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.